Due to the insulin-independent mechanism of action of SGLT-2is, the risk of hypoglycemia with these agents is low in patients with T2D but may increase when SGLT-2is are used concomitantly with insulin or sulfonylureas (insulin secretagogues) [28,29]. Here, INS is linked to Hypoglycemia.